0001104659-22-084763.txt : 20220801 0001104659-22-084763.hdr.sgml : 20220801 20220801170142 ACCESSION NUMBER: 0001104659-22-084763 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220728 FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gilad Oren CENTRAL INDEX KEY: 0001929300 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 221125598 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 tm2222147-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-07-28 0 0001781983 Aprea Therapeutics, Inc. APRE 0001929300 Gilad Oren 535 BOYLSTON STREET BOSTON MA 02116 0 1 0 0 President, CEO Common Stock 2022-07-28 4 A 0 101300 0 A 330314 D Stock Option (right to Buy) 1.09 2022-07-28 4 A 0 148700 0 A 2032-07-28 Common Stock 148700 148700 D These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 33,766 shares on July 28, 2023, (ii) 33,767 shares on July 28, 2024 and (iii) 33,767 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. /s/ Scott M. Coiante, attorney-in-fact 2022-08-01